We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Epitome to Develop Multiplex Assay Reagents for EMD
News

Epitome to Develop Multiplex Assay Reagents for EMD

Epitome to Develop Multiplex Assay Reagents for EMD
News

Epitome to Develop Multiplex Assay Reagents for EMD

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Epitome to Develop Multiplex Assay Reagents for EMD "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Epitome Biosystems has announced that it has signed a licensing and development agreement with EMD Biosciences for products based on Epitome's proprietary EpiTag™ technology.

Epitome will develop reagents for the quantitative measurement of key intracellular signaling proteins.

The companies will collaborate on development and the products will be marketed and sold for research applications on a world-wide basis by EMD Biosciences under its well-known Novagen® and Calbiochem® brands.

Epitome will receive a technology access fee, milestone-based development payments, and royalties on product sales.

Epitome's EpiTag technology is designed to enable the identification of amino acid sequences or "tags" within a protein.

Antibodies raised against peptides containing the tags, rather than the entire protein, have predetermined specificity and high affinity.

Similarly, measurement in an EpiTag assay is made on the peptide fragment, released from the protein by digestion, rather than on the entire protein.

By reducing the measurement system to a peptide level, Epitome provides a universal, efficient and scalable method for developing and conducting multiplex protein assays.

Neal Gordon, Ph.D., President of Epitome stated, "We are extremely pleased to have a company with the reputation of EMD Biosciences become one of our early technology adopters.”

“They have an outstanding history of innovation and we are looking forward to helping them expand their product line."

"The EpiTag system is a simple yet powerful approach to develop robust multiplex immunoassays," said Robert Mierendorf, Ph.D., CTO of EMD Biosciences.

"We are excited about partnering with Epitome Biosystems to develop unique tools for the study of cell signaling pathways," he continued.

Advertisement